Key result
Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Why the study?
Does enoxaparin (40 mg) prevent deep-vein thrombosis compared to standard unfractionated heparin in high-risk hospitalized medical patients?
Does enoxaparin (40 mg) prevent deep-vein thrombosis compared to standard unfractionated heparin in high-risk hospitalized medical patients?
Enoxaparin is an effective and safer alternative to standard unfractionated heparin for DVT prophylaxis in high-risk hospitalized medical patients.
Answers are grounded in this paper and cite their sources.
Supports enoxaparin preference for DVT prophylaxis in high-risk medical inpatients; confirms noninferior efficacy with superior safety versus unfractionated heparin.
In a multicentre, randomized, double-blind controlled trial comparing the low-molecular-weight heparin enoxaparin (40 mg) with a standard unfractionated heparin (Ca-heparin, 3 × 5,000 U) in deep-vein thrombosis prophylaxis in a high-risk group of 959 hospitalized medical patients, enoxaparin was at least as efficacious as standard heparin, with fewer adverse events.
No takes yet. Share an insight, caveat, or question.
Lechler et al. (2009) studied this question. Enoxaparin was at least as efficacious as standard unfractionated heparin for deep-vein thrombosis prophylaxis in high-risk hospitalized medical patients, with fewer adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: